Clinical trial NCT01169129: Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases
Official title: Surgery and Whole Brain Radiotherapy Versus Whole Brain Radiotherapy and Radiosurgery for 1-3 Resectable Brain Metastases: Phase III Prospective Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Metastases
Cancer
Keywords: brain metastases
radiosurgery
neurosurgery
surgery
radiotherapy
resectable brain metastases
Lead sponsor: Barretos Cancer Hospital
Sponsor class: OTHER
First posted: 2010-07-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients in good general condition with resectable brain metastases, looks better with more intense treatment of metastases. This local treatment has been accomplished with surgery or radiosurgery. However, there are no randomized studies comparing these two types of treatment. The purpose of this study is to make this.

Detailed description: Patients in good general condition with resectable 1-3 brain metastases will be randomized to surgery and whole brain radiotherapy and whole brain radiotherapy and radiosurgery. Initially we will evaluate the feasibility of carrying out the study with 15 patients in each arm, and after, we will follow with the primary end-point of comparing the toxicity of the exclusively radiotherapy arm with complications of the surgical arm. As a secondary end-point, we will evaluate local recurrence-free survival, overall survival, distance cerebral relapse-free survival (metachronous brain metastasis), free of neurological progression survival, free of neurological death survival, free of dependent life (another person)survival , steroid-free survival and quality of life.

Eligibility criteria: Inclusion Criteria:

* Histopathology of primary tumors: all but primary small cell cancer, germ cell tumors, leukemia, lymphoma, or primary central nervous system.
* Primary-site: controlled, meaning operated and / or irradiated; without detectable local tumor activity
* Lack of extra-cranial metastases
* Absence of prior brain irradiation
* Number of brain metastases: 1-3
* Location of brain metastases: brain regions eligible for surgery (non-eloquent areas) and RC (metastases with largest diameter ≤ 3 cm, volume \<15 mL, and\> 5 mm from the optic chiasm, optic nerves, thalamus, hypothalamus, basal ganglia base, optic tract, optic radiation, midbrain, pons, medulla, corpus callosum, internal capsule, hippocampus and amygdala, and \<10 ml of brain tissue receiving ≥ 12 Gy).
* Metastasis-that does not cause significant mass effect and hydrocephalus or herniation requiring urgent surgical intervention
* Second uncontrolled primary tumor site: none, except non-melanoma skin cancer
* Absence of comorbid conditions that prevents surgery for resection of brain metastases
* Absence of connective tissue disease such as lupus erythematosus or scleroderma
* Patients in chemotherapy need to have their chemotherapy treatment suspended.
* Patients must consent to be followed by clinical staff of the Barretos Cancer Hospital (HCB).
* KPS: ≥ 70%
* Neutrophils ≥ 1800 cells / mL until 14 days prior to study entry
* Platelets ≥ 100,000 cells / mL until 14 days prior to study entry
* Hemoglobin ≥ 10 g / dL 14 days prior to entering the study (transfusion is allowed to achieve required concentration)
* Creatinine ≤ 1.7 mg / dL 14 days prior to study entry
* BUN ≤ 30 mg / dL 14 days prior to entry on study
* Bilirubin ≤ 2 mg / dL 14 days prior to study entry
* TGO/TGP Up to three times normal on examination until 14 days prior to study entry Prothrombin time-INR \<1.4 at examination until 14 days prior to study entry
* Systolic pressure ≤ 160 mm Hg and diastolic pressure ≤ 90 mm Hg at examination until 14 days prior to study entry Electrocardiogram-without acute myocardial infarction in examination until 14 days prior to study entry
* No active bleeding or pathological condition that entails high risk of bleeding
* Negative pregnancy test at least 14 days prior to study entry
* Informed Consent: The patient will be informed of the investigational nature of treatment and only enter the study after agreeing to participate in the study signed a consent form that informs the side effects and possible benefits and potential of both modalities treatment.

Exclusion Criteria:

* Metastasis in the posterior fossa, because this patient will be operated.

Primary outcomes:
measure: feasibility
timeFrame: 1 year
Secondary outcomes:
measure: complications and toxicity
timeFrame: 1 year
Other outcomes:
Locations:
city: Barretos
country: Brazil
facility: Barretos Cancer Hospital
state: São Paulo
Study officials:
affiliation: Barretos Cancer Hospital
name: Ricardo A Nakamura, MD
role: PRINCIPAL_INVESTIGATOR
References: